Becotatug vedotin
Based on 1 Customer Validation
Becotatug vedotin (MRG003) is an Antibody-Drug Conjugate (ADC) that consists of an anti-EGFR humanized IgG1 monoclonal antibody Becotatug (HY-P990049) and MMAE (HY-15162). These two parts are connected through a valine-citrulline (valine-citrulline) linker, where the linker and MMAE constitute the ADC's Drug-Linker conjugate VcMMAE (HY-15575). Becotatug vedotin is also an inhibitor of tubulin, which can be used for the research of cancer, such as squamous cell carcinomas of the head and neck, nasopharyngeal carcinoma.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 96.99%
- 분자량:149470 (average)
-
보관:Shipping with dry ice
-80°C, protect from light
Biological Activity
제품 설명
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Product Details
Chemical Information
-
Appearance Liquid
-
분자량 149470 (average)
-
Color Colorless to light yellow
-
SMILES
[Becotatug vedotin]
-
Synonyms
MRG003
-
선적
Shipping with dry ice.
-
보관
-80°C, protect from light
순도&문서
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- Becotatug vedotin
- MRG003
- MRG 003
- MRG-003
- Antibody-Drug Conjugates (ADCs)
- EGFR
- Antibody-Drug Conjugates
- ADC
- Epidermal growth factor receptor
- ErbB-1
- HER1
- monomethyl auristatin E
- nasopharyngeal carcinoma
- squamous cell carcinomas of the head and neck
- valine-citrulline linker
- epidermal growth factor receptor
- humanized immunoglobulin G1 monoclonal antibody
- Inhibitor
- inhibitor
- inhibit